DFX Intelligence
Private Equity Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Firms / A••••••• C•••••• L••
A••••••• C•••••• L••
A••••••• C•••••• are experienced private equity investors dedicated to the UK and European healthcare industry, focused on creating a positive healthcare impact
Classification
- Class
- Buyout firmconfirmed, confidence 85%
- Basis
- R6: 3 of 3 distinct vehicles are sworn Private Equity Funds; 2 reported gross assets on a filing in 2022 or later
- Size band
- Lower middle marketdefined by: proxy: $0.38bn Private Equity Fund GAV on the Form ADV filed 2023-05-11
Classification history (1)
- Sep 13, 2026Buyout firm (confirmed, 85%, cls-pe-1)R6: 3 of 3 distinct vehicles are sworn Private Equity Funds; 2 reported gross assets on a filing in 2022 or later
Regulatory footprint (Form ADV)
- Adviser type
- exempt reporting adviser
- Form ADV filings
- Mar 27, 2012 to May 11, 2023
- RAUM
- unknownregulatory assets under management of the adviser; not dry powder, not a fund size
- PE funds, latest filing
- 2
- PE fund GAV, latest filing
- $381Mreported gross assets (Form ADV), not fund size
- All private fund GAV
- $381Mevery private fund type, latest filing
- 2024 PE fund GAV
- unknownsum over funds typed Private Equity Fund with a 2024 or later as-of date
- PE share of funds, lifetime
- 100%
- Fund type mix
- filed 2023-05-11, latest gav Private Equity Fund $381M, latest counts Private Equity Fund 2, lifetime distinct Private Equity Fund 3
- Employees
- unknown
- Headquarters
- London, United Kingdom
- Office address
- SECOND FLOOR, 21 WHITEFRIARS STREET, London, EC4Y 8JJ
- Business phone
- 44 20 3475 1710
Stated criteria beside observed behaviour
77 observed deals
Stated by the firm
- Sectors
- healthcare, life sciences
- Geography
- Europe, United Kingdom
- Revenue
- not stated or not yet read
- EBITDA
- not stated or not yet read
- Enterprise value
- not stated or not yet read
- Equity check
- not stated or not yet read
- Control
- not stated or not yet read
- Thesis
- We invest through both growth capital and buyouts in ambitious, growing UK and European SME businesses operating across healthcare providers, digital health, medical products & devices, life sciences & pharmaceuticals, and healthcare services.
Observed from deals on record
- roles
- unknown 77
- period
- to unknown, from unknown, undated holdings 77, dated observations 0
- window
- last unknown, first unknown
- control
- unknown 77
- companies
- 77
- geography
- investments
- 77
- seller kinds
- transactions
- 0
- cadence by year
- platform add on
- add ons 0, platforms 0, add ons per platform unknown
- sector known for
- 1
- disclosed value usd
- n 0
- sector distribution
- count 1, share 0.013, value consumer services, examples Healthcare Services Company
- holding period years
- n 0
- repeat counterparties
- subsector distribution
- count 1, share 0.013, value landscaping, examples Healthcare Services Company
77 companies on the graph (0 transactions); most in consumer services (1); no dated observations
Funds
3 on record
| Fund | Vehicle | Vintage | Reported gross assets (Form ADV), not fund size | GAV by year | Form D sold | Lifecycle |
|---|---|---|---|---|---|---|
| A••••••• H••••••••• F••• I• L••• ADV: Private Equity Fund | buyout or unlabelled | 2021 first reported on Form ADV | $243M as of May 11, 2023 | no Form D | Unknown | |
| A••••••• H••••••••• I•• L••• ADV: Private Equity Fund | buyout or unlabelled | 2021 first reported on Form ADV | $138M as of May 11, 2023 | no Form D | Unknown | |
| F••••• S••••• V•••••• P••••••• L• ADV: Private Equity Fund | buyout or unlabelled | unknown | $113,556 as of Jun 23, 2020 | no Form D | Wound down |
Team
19 current, 2 former
Managing partner (2)
- D•••• P••••• · Founding Partner · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- S•• G••• · Managing Partner · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
Partner (6)
- F••• D•••• P••••• · Designated Member · since Apr 1, 2006 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- R••• C•••••••• R••••• P••• · Member · since Oct 1, 2017 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- R••• C•••••••• R••••• P••• · Partner · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- S•••• S••• · I•••••ment Manager · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- S••••• J•••• C••••• G••• · Designated Member · since Jan 1, 2016 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- S•••••• L•••••••• · I•••••ment Manager · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
Principal (4)
- A••• C••••••••• · I•••••ment Director · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- C•••••••• S••••• · I•••••ment Director · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- L••••• M••••• · I•••••ment Director · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- S•••• A•••• · Portfolio Director · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
Platform (6)
- J•••• H••••• · Partner & CFO · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- J••• M••••• · Talent and Human Capital Director · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- J••••••••• H••••• · Operations and Finance Manager · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- M••••• C••••••••• · Finance and Operations Associate · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- M••••••• W••••••••• · Executive Assistant · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
- V••••••• O••••••• · Marketing Executive · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
Other (1)
- E••• B•••••• · I•••••ment Executive · start date unknown I•••••ment organization websites (team, portfolio, strategy, criteria, news)
2 former (kept with end dates)
- A•••• P• M••••••••• · Designated Member · Apr 1, 2006 to Feb 11, 2016 Inference
- S•••••• A•••• · Designated Member · Apr 1, 2006 to Feb 11, 2016 Inference
Portfolio
77 relationships, 0 platforms, 0 add-ons
Transactions
0 on record
No transaction naming this firm has been collected yet. The deal tape is read from SEC filings and cited announcements.
Placement agents, lenders, advisers and co-investors
1 relationships
Placement agents (1)
- B• S••••••••• L•• 1 shared · one time · last Jan 1, 2021
LP commitments
0 disclosed
No LP commitment collected yet. An LP edge needs a public disclosure with a quote, such as a pension plan’s report or an announcement naming the LP.
Events
26 most recent
- Sep 17, 2026I•••••ment type: MBO Sub sector: P•••••ceutical & L••• S••••••• 1•••
- Sep 17, 2026I•••••ment type: MBO Sub sector: Medtech & M•••••• P••••••• C•••••••••
- Sep 17, 2026I•••••ment type: G••••• Sub sector: Medtech & M•••••• P••••••• E••••••••
- Sep 17, 2026I•••••ment type: MBO Sub sector: H••••• & Social C••• H••••••
- Sep 17, 2026I•••••ment type: BIMBO Sub sector: H••••• & Social C••• H•••
- Sep 17, 2026I•••••ment type: BIMBO Sub sector: Medtech & M•••••• P••••••• i2a
- Sep 17, 2026I•••••ment type: Replacement & G••••• Sub sector: H••••• & Social C••• I•••••• H•••••••
- Sep 17, 2026I•••••ment type: MBI Sub sector: P•••••ceuticals & L••• S••••••• K•••• P•••••
- Sep 17, 2026I•••••ment type: MBO Sub sector: H••••• & Social C••• L••••• O•••••
- Sep 17, 2026I•••••ment type: G••••• Sub sector: D•••••• H••••• M••••• M••••••
- Sep 17, 2026I•••••ment type: MBO Sub sector: H••••• and Social C••• O•••••• H•••• S••••••
- Sep 17, 2026I•••••ment type: MBO & G••••• Sub sector: H••••• & Social C••• R•••••••• H•••••••••
- Sep 17, 2026I•••••ment type: MBO Sub sector: Medtech & M•••••• P••••••• S••••• M••••••
- Sep 17, 2026I•••••ment type: BIMBO Sub sector: H••••• & Social C••• S•••••• C••• & C••••••••
- Sep 17, 2026I•••••ment type: Buyout Sub sector: H••••• & Social C••• By the B•••••
- Sep 17, 2026I•••••ment type: Founding & G••••• Sub sector: H••••• & Social C••• C•••••••••
- Sep 17, 2026I•••••ment type: MBO Sub sector: H••••• & Social C••• M• C••• H•••••••
- Sep 17, 2026I•••••ment type: Replacement & G••••• Sub sector: P•••••ceuticals & L••• S••••••• N•••••••••
- Sep 17, 2026I•••••ment type: Buy-in Sub sector: H••••• & Social C••• S•••••••
- Sep 17, 2026I•••••ment type: Replacement & G••••• Sub sector: Medtech and M•••••• P••••••• U••••••
- Sep 17, 2026I•••••ment type: Replacement & G••••• Sub sector: D•••••• H••••• W•••••••••
- Sep 17, 2026I•••••ment type: Replacement & G••••• Sub sector: Medtech and M•••••• P••••••• Z•••••
- Sep 1, 2026Adviser CRD 159522 is not on the SEC registered or exempt adviser roster of 2026-09-01
- Sep 11, 20251••• S•••••••• 2025 H••• A••••••• Marc Holl as Chief Quality Officer and Strengthens S••••• Leadersh...
- Aug 14, 20251••• A••••• 2••• K•••• P••••• A••••••• N•• C••
- Mar 27, 2012A••••••• C•••••• L•• first filed Form ADV in the extract (ERA)